LOPID® (Parke-Davis)
(Gemfibrozil Tablets, USP)ESCRIPTION
LOPID® (gemfibrozil) is a lipid regulating agent. It is available as tablets for oral administration. Each tablet contains 600 mg gemfibrozil. LOPID is a lipid regulating agent which decreases serum triglycerides and very low density lipoprotein (VLDL) cholesterol, and increases high density lipoprotein HDL cholesterol. Modest decreases in total and low density lipoprotein (LDL) cholesterol is observed with LOPID therapy. LOPID raises HDL-cholesterol significantly. LOPID increases levels of high density lipoprotein (HDL) subfractions HDL 2 and HDL 3 , as well as apolipoproteins AI and AIIINDICATIONS AND USAGE
LOPID (gemfibrozil) is indicated as adjunctive therapy to diet for:Treatment of adult patients with very high elevations of serum cholesterol levels and who do not respond adequately to a determined dietary effort to control them. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides.
PRECAUTIONS
1. Initial Therapy --Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal. Before instituting LOPID therapy, every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities.2. Continued Therapy --Periodic determination of serum lipids should be obtained, and the drug withdrawn if lipid response is inadequate after three months of therapy.